• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

BROMOCRIPTINE Drug Record

  • Summary
  • Interactions
  • Claims
  • BROMOCRIPTINE chembl:CHEMBL493 Approved

    Alternate Names:

    BROMOCRIPTINE
    SANDOZ 15-754
    PARLODEL
    CB-154
    2-BROMOERGOCRYPTINE
    PLO154
    2-BROMO-Α-ERGOKRYPTINE
    2-BROMO-ALPHA-ERGOKRYPTIN
    BROMOCRYPTINE
    2-BROMO-Α-ERGOCRYPTINE
    BROMOCRIPTINA
    2-BROMO-ALPHA-ERGOKRYPTINE
    PARLODEL®
    (5'ALPHA)-2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)-3',6',18-TRIOXOERGOTAMAN
    2-BROMO-Α-ERGOKRYPTIN
    BROMOERGOCRYPTINE
    BROMOERGOCRIPTINE
    (5'ALPHA)-2-BROMO-12'-HYDROXY-5'-ISOBUTYL-2'-ISOPROPYL-3',6',18-TRIOXOERGOTAMAN
    2-BROMO-ALPHA-ERGOCRYPTINE
    BROMOCRIPTINUM
    (5'ALPHA)-2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)ERGOTAMAN-3',6',18-TRIONE
    drugbank:01200
    chemidplus:25614-03-3
    pubchem.compound:31101
    rxcui:1760
    chembl:CHEMBL493

    Drug Info:

    Drug Class antiparkinson agents
    Year of Approval 1978
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antidiabetic
    Drug Categories anti-parkinson drugs
    Drug Categories adrenergic agonists
    Drug Categories adrenergic alpha-1 receptor agonists
    Drug Categories adrenergic alpha-1 receptor antagonists
    Drug Categories adrenergic alpha-2 receptor agonists
    Drug Categories adrenergic alpha-agonists
    Drug Categories adrenergic alpha-antagonists
    Drug Categories adrenergic antagonists
    Drug Categories agents producing tachycardia
    Drug Categories agents that produce hypertension
    Drug Categories antidepressive agents
    Drug Categories central nervous system depressants
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 cyp3a4 inhibitors
    Drug Categories cytochrome p-450 cyp3a4 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 enzyme inhibitors
    Drug Categories cytochrome p-450 substrates
    Drug Categories ergot alkaloids and derivatives
    Drug Categories ergot-derivative dopamine receptor agonists
    Drug Categories genito urinary system and sex hormones
    Drug Categories heterocyclic compounds, fused-ring
    Drug Categories p-glycoprotein inhibitors
    Drug Categories p-glycoprotein substrates
    Drug Categories prolactine inhibitors
    Drug Categories serotonin 5-ht2 receptor agonists
    Drug Categories serotonin agents
    Drug Categories serotonin receptor agonists
    (4 More Sources)

    Publications:

    Doknic et al., 2002, Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine., Eur. J. Endocrinol.
    Figueroa et al., 1993, [Pharmacological modification of prolactinemia. Effects on cellular immune function in normal subjects]., Rev Med Chil
    Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem
    Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy
    Palestine et al., 1987, Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat., J. Clin. Invest.
    de Leeuw van Weenen et al., 2010, The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells., Biochem. Pharmacol.
    Cussac et al., 2008, Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells., Eur. J. Pharmacol.
    Burdman et al., 2001, Bromocriptine and the expression of c-myc and c-fos in human prolactinomas., Neurol. Res.
    Pelletier et al., 1991, Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus., Neurosci. Lett.
    Knight et al., 2009, Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists., Mol. Pharmacol.
    Orlowski et al., 1998, Bromocriptine modulates P-glycoprotein function., Biochem. Biophys. Res. Commun.
    Shiraki et al., 2002, Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells., Jpn. J. Cancer Res.
    Gibson A et al., 1979, The effects of bromocriptine on pre-synaptic and post-synaptic alpha-adrenoceptors in the mouse vas deferens., J Pharm Pharmacol
    Lim et al., 2008, Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage., Pharmacol. Res.
    Cavallotti et al., Age-related changes in dopamine D2 receptors in rat heart and coronary vessels., Clin. Exp. Pharmacol. Physiol.
    Lahlou, 1999, Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats., Fundam Clin Pharmacol
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Lahlou et al., 2003, Blunted central bromocriptine-induced tachycardia in conscious, malnourished rats., Pharmacol. Toxicol.
    Stefaneanu et al., 2001, Dopamine D2 receptor gene expression in human adenohypophysial adenomas., Endocrine
    Lahlou et al., 2000, Effects of long-term pretreatment with isoproterenol on bromocriptine-induced tachycardia in conscious rats., Can. J. Physiol. Pharmacol.
    Ohta et al., 2003, Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes., Life Sci.
    Wynalda et al., 1997, Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen., Drug Metab. Dispos.
  • BROMOCRIPTINE   SAG

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    3494043


    Sources:
    NCI

  • BROMOCRIPTINE   GDNF

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12770616


    Sources:
    NCI

  • BROMOCRIPTINE   NPY

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1679226


    Sources:
    NCI

  • BROMOCRIPTINE   FOS

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11680511


    Sources:
    NCI

  • BROMOCRIPTINE   LEP

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12088923


    Sources:
    NCI

  • BROMOCRIPTINE   DRD5

    Interaction Score: 0.14

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Full agonist
    Endogenous Drug? False

    PMIDs:
    18691132


    Sources:
    DrugBank GuideToPharmacology

  • BROMOCRIPTINE   DRD2

    Interaction Score: 0.11

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name bromocriptine mesylate,Cycloset, Ergoset
    Novel drug target Established target
    Specific Action of the Ligand Full agonist

    PMIDs:
    12010185 10626749 11752352 12753422 11444429 10721819 18691132 10641988


    Sources:
    DrugBank TdgClinicalTrial TEND GuideToPharmacology TTD

  • BROMOCRIPTINE   HTR2B

    Interaction Score: 0.11

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    18691132 10641988 18703043


    Sources:
    DrugBank GuideToPharmacology

  • BROMOCRIPTINE   HTR1D

    Interaction Score: 0.11

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Partial agonist
    Endogenous Drug? False

    PMIDs:
    18691132 10641988


    Sources:
    DrugBank GuideToPharmacology

  • BROMOCRIPTINE   ADRA2B

    Interaction Score: 0.1

    Interaction Types & Directionality:
    antagonist (inhibitory)
    agonist (activating)

    Interaction Info:
    Endogenous Drug? False
    Specific Action of the Ligand Antagonist

    PMIDs:
    20138024 18691132 10641988


    Sources:
    DrugBank GuideToPharmacology

  • BROMOCRIPTINE   HTR1B

    Interaction Score: 0.09

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Partial agonist
    Endogenous Drug? False

    PMIDs:
    18691132 10641988


    Sources:
    DrugBank GuideToPharmacology

  • BROMOCRIPTINE   IL2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8191163


    Sources:
    NCI

  • BROMOCRIPTINE   DRD3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Direct Interaction? True
    Endogenous Drug? False
    Specific Action of the Ligand Partial agonist

    PMIDs:
    18691132 10641988


    Sources:
    DrugBank TdgClinicalTrial GuideToPharmacology

  • BROMOCRIPTINE   ADRA2C

    Interaction Score: 0.08

    Interaction Types & Directionality:
    antagonist (inhibitory)
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    20138024 18691132 10641988


    Sources:
    DrugBank GuideToPharmacology

  • BROMOCRIPTINE   MYC

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11680511


    Sources:
    NCI

  • BROMOCRIPTINE   DRD4

    Interaction Score: 0.07

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    18691132


    Sources:
    DrugBank GuideToPharmacology

  • BROMOCRIPTINE   HTR2C

    Interaction Score: 0.07

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Partial agonist
    Endogenous Drug? False

    PMIDs:
    18691132 10641988 18703043


    Sources:
    DrugBank GuideToPharmacology

  • BROMOCRIPTINE   ADRA2A

    Interaction Score: 0.07

    Interaction Types & Directionality:
    antagonist (inhibitory)
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False

    PMIDs:
    20138024 18691132 10641988


    Sources:
    DrugBank GuideToPharmacology

  • BROMOCRIPTINE   HTR7

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    18996971


    Sources:
    DrugBank

  • BROMOCRIPTINE   ADRA1D

    Interaction Score: 0.05

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    10641988


    Sources:
    DrugBank

  • BROMOCRIPTINE   ADRA1B

    Interaction Score: 0.05

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    10641988 43367


    Sources:
    DrugBank

  • BROMOCRIPTINE   HTR1A

    Interaction Score: 0.05

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Partial agonist
    Endogenous Drug? False

    PMIDs:
    18691132 10641988


    Sources:
    DrugBank GuideToPharmacology

  • BROMOCRIPTINE   HTR2A

    Interaction Score: 0.05

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Partial agonist
    Endogenous Drug? False

    PMIDs:
    18691132 10641988 18703043


    Sources:
    DrugBank GuideToPharmacology

  • BROMOCRIPTINE   DRD1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Partial agonist
    Endogenous Drug? False

    PMIDs:
    18691132


    Sources:
    DTC DrugBank GuideToPharmacology

  • BROMOCRIPTINE   HTR6

    Interaction Score: 0.03

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Specific Action of the Ligand Full agonist
    Endogenous Drug? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • BROMOCRIPTINE   ADRA1A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    10641988 43367


    Sources:
    DrugBank

  • BROMOCRIPTINE   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9514944 11856485


    Sources:
    NCI

  • BROMOCRIPTINE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9321526


    Sources:
    NCI

  • BROMOCRIPTINE   NFE2L2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18455424


    Sources:
    NCI

  • BROMOCRIPTINE   VDR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • BROMOCRIPTINE   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • BROMOCRIPTINE   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DrugBank: DB01200

    • Version: 5.1.7

    Alternate Names:
    BROMOCRIPTINE DrugBank Drug Name
    25614-03-3 CAS Number
    Apo-Bromocriptine Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy
    Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem
    de Leeuw van Weenen et al., 2010, The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells., Biochem. Pharmacol.

  • TEND: BROMOCRIPTINE

    • Version: 01-August-2011

    Alternate Names:
    BROMOCRIPTINE Primary Drug Name

    Drug Info:
    Year of Approval 1978
    Drug Class antiparkinson agents

    Publications:

  • TdgClinicalTrial: BROMOCRIPTINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidiabetic
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: BROMOCRIPTINE

    • Version: 14-September-2017

    Alternate Names:
    C317 NCI drug code

    Drug Info:

    Publications:
    Ohta et al., 2003, Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes., Life Sci.
    Wynalda et al., 1997, Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen., Drug Metab. Dispos.
    Figueroa et al., 1993, [Pharmacological modification of prolactinemia. Effects on cellular immune function in normal subjects]., Rev Med Chil

  • DTC: BROMOCRIPTINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL493 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Bromocriptine

    • Version: 2020.06.01

    Alternate Names:
    D06YFA TTD Drug ID

    Drug Info:

    Publications:

  • GuideToPharmacology: 135650026

    • Version: 29-September-2020

    Alternate Names:
    BROMOCRIPTINE GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL493

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21